ALLOGENE THERAPEUTICS INC (ALLO) Stock Income Statement
NASDAQ:ALLO - Nasdaq - US0197701065 - Common Stock - Currency: USD
| 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 22.00K | 95.00K | 240.00K | 38.49M | 0.00 | |||
| Operating Expenses | 257.50M | 314.59M | 335.69M | 294.28M | 258.24M | |||
| Research and Development | 192.30M | 242.91M | 256.39M | 220.18M | 192.99M | |||
| Selling, General, and Administrative Expenses | 65.20M | 71.67M | 79.31M | 74.11M | 65.26M | |||
| Operating Income | -257.48M | -314.49M | -335.45M | -255.79M | -258.24M | |||
| Interest Income/Expense | 16.05M | 18.31M | 4.57M | 1.71M | 9.16M | |||
| Other Income/Expense | N/A | -17.84M | -1.75M | -2.93M | -1.14M | |||
| Non Recurring Items | -15.72M | -13.24M | N/A | N/A | 0.00 | |||
| Income Before Taxes | -257.15M | -327.26M | -332.63M | -257.01M | -250.22M | |||
| Income Tax | 443.00K | N/A | N/A | 0.00 | 0.00 | |||
| Net Income | -257.59M | -327.26M | -332.63M | -257.01M | -250.22M | |||
| EBITDA | -243.84M | -300.29M | -321.15M | -245.34M | -250.65M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -1.32 | -2.09 | -2.32 | -1.89 | -2.08 | |||
| Non GAAP EPS | -1.33 | -2.01 | -2.32 | -1.89 | -2.08 | |||
| Statistics | ||||||||
| Profit Margin | -1170863.64% | -344489.47% | -138595.83% | -667.73% | N/A | |||
| Operating Profit Margin | -1170372.73% | -331044.21% | -139770.83% | -664.56% | N/A | |||
All data in USD